Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials

IF 5.9 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

American journal of preventive cardiology Pub Date : 2025-09-17 DOI:10.1016/j.ajpc.2025.101303

Beatriz Araújo , Giang Son Arrighini , Flávia Queiroga , Ensieh Sadat Mansouri , André Rivera , Wellgner Fernandes Oliveira Amador , Ivo Queiroz , Maria Antônia Costa Cruz Akabane , Leo N Consoli , Milene Vitória Sampaio Sobral , Lucas M. Barbosa , Luciana Gioli-Pereira , Erin D. Michos

{"title":"Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials","authors":"Beatriz Araújo , Giang Son Arrighini , Flávia Queiroga , Ensieh Sadat Mansouri , André Rivera , Wellgner Fernandes Oliveira Amador , Ivo Queiroz , Maria Antônia Costa Cruz Akabane , Leo N Consoli , Milene Vitória Sampaio Sobral , Lucas M. Barbosa , Luciana Gioli-Pereira , Erin D. Michos","doi":"10.1016/j.ajpc.2025.101303","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Obicetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor with promising lipid-lowering effects. While earlier CETP inhibitors have shown inconsistent cardiovascular outcomes and safety concerns, the efficacy and safety of obicetrapib remain under active investigation.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Embase, and Cochrane Central databases for randomized controlled trials (RCTs) comparing obicetrapib versus placebo in adults with dyslipidemia or at high cardiovascular risk. We pooled mean differences (MDs) with 95 % confidence intervals (CI) with a random effects model. We used R software version 4.4.2 for statistical analysis.</div></div><div><h3>Results</h3><div>We included 7 RCTs comprising 3381 participants, of whom 2151 (63 %) received obicetrapib. The mean age was 64.3 years, and 36 % were women. Compared with placebo, obicetrapib significantly reduced mean LDL-C (MD: -37.21 %; 95 % CI: -41.53 to -32.90; <em>p</em> < 0.01; I<sup>2</sup>=64 %), lipoprotein(a) (MD: -37.16 %; 95 % CI: -43.63 to -30.70; <em>p</em> < 0.01, I<sup>2</sup>=48 %), apolipoprotein B (MD: -24.65 %; 95 % CI: -28.71 to -20.59; <em>p</em> < 0.01; I²=83 %), non-HDL-C (MD: -31.90 %; 95 % CI: -34.81 to -28.99; <em>p</em> < 0.01; I<sup>2</sup>=0 %), and triglyceride levels (MD: -7.21 %; 95 % CI: -11.13 to -3.30; <em>p</em> < 0.01; I<sup>2</sup>=0 %). Interestingly, obicetrapib also reduced the incidence of new-onset diabetes (RR: 0.88; 95 % CI: 0.80 to 0.97; <em>p</em> = 0.01; I²=0 %). In contrast, obicetrapib significantly increased HDL-C (MD: 142.17 %; 95 % CI: 117.56 to 166.78; <em>p</em> < 0.01; I<sup>2</sup>=98.3 %), total cholesterol (MD: 11.94 %; 95 % CI: 5.61 to 18.28; <em>p</em> = 0.01; I<sup>2</sup>=91 %), and apolipoprotein A1 concentrations (MD: 52.76 %; 95 % CI: 41.87 to 63.66; <em>p</em> < 0.01; I²=94 %). There were no significant differences in adverse events.</div></div><div><h3>Conclusion</h3><div>Among patients with dyslipidemia and/or high cardiovascular risk, obicetrapib significantly reduces LDL-C, lipoprotein(a), apolipoprotein B, and non-HDL-C. No significant differences were observed in adverse events, supporting the favorable safety profile of obicetrapib.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"24 ","pages":"Article 101303"},"PeriodicalIF":5.9000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of preventive cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666667725003782","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Obicetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor with promising lipid-lowering effects. While earlier CETP inhibitors have shown inconsistent cardiovascular outcomes and safety concerns, the efficacy and safety of obicetrapib remain under active investigation.

Methods

We systematically searched PubMed, Embase, and Cochrane Central databases for randomized controlled trials (RCTs) comparing obicetrapib versus placebo in adults with dyslipidemia or at high cardiovascular risk. We pooled mean differences (MDs) with 95 % confidence intervals (CI) with a random effects model. We used R software version 4.4.2 for statistical analysis.

Results

We included 7 RCTs comprising 3381 participants, of whom 2151 (63 %) received obicetrapib. The mean age was 64.3 years, and 36 % were women. Compared with placebo, obicetrapib significantly reduced mean LDL-C (MD: -37.21 %; 95 % CI: -41.53 to -32.90; p < 0.01; I²=64 %), lipoprotein(a) (MD: -37.16 %; 95 % CI: -43.63 to -30.70; p < 0.01, I²=48 %), apolipoprotein B (MD: -24.65 %; 95 % CI: -28.71 to -20.59; p < 0.01; I²=83 %), non-HDL-C (MD: -31.90 %; 95 % CI: -34.81 to -28.99; p < 0.01; I²=0 %), and triglyceride levels (MD: -7.21 %; 95 % CI: -11.13 to -3.30; p < 0.01; I²=0 %). Interestingly, obicetrapib also reduced the incidence of new-onset diabetes (RR: 0.88; 95 % CI: 0.80 to 0.97; p = 0.01; I²=0 %). In contrast, obicetrapib significantly increased HDL-C (MD: 142.17 %; 95 % CI: 117.56 to 166.78; p < 0.01; I²=98.3 %), total cholesterol (MD: 11.94 %; 95 % CI: 5.61 to 18.28; p = 0.01; I²=91 %), and apolipoprotein A1 concentrations (MD: 52.76 %; 95 % CI: 41.87 to 63.66; p < 0.01; I²=94 %). There were no significant differences in adverse events.

Conclusion

Among patients with dyslipidemia and/or high cardiovascular risk, obicetrapib significantly reduces LDL-C, lipoprotein(a), apolipoprotein B, and non-HDL-C. No significant differences were observed in adverse events, supporting the favorable safety profile of obicetrapib.

查看原文本刊更多论文

obicetrapib对血脂异常患者的疗效和安全性：一项随机对照试验的最新荟萃分析

obicetrapib是一种新型的胆固醇酯转移蛋白（CETP）抑制剂，具有良好的降脂效果。虽然早期的CETP抑制剂显示出不一致的心血管结局和安全性问题，但obicetrapib的有效性和安全性仍在积极研究中。方法：我们系统地检索PubMed、Embase和Cochrane Central数据库，以比较obicetrapib和安慰剂在成人血脂异常或心血管高危人群中的疗效的随机对照试验（rct）。我们用随机效应模型汇总了95%置信区间（CI）的平均差异（MDs）。我们使用R软件4.4.2版本进行统计分析。我们纳入了7项随机对照试验，包括3381名受试者，其中2151名（63%）接受了obicetrapib。平均年龄64.3岁，女性占36%。与安慰剂相比,obicetrapib显著降低意味着低密度(MD: -37.21%; 95%置信区间:-41.53 - -32.90;p & lt; 0.01; I2 = 64%)、脂蛋白(a) (MD: -37.16%; 95%置信区间:-43.63 - -30.70;p & lt; 0.01, I2 = 48%)、载脂蛋白B (MD: -24.65%; 95%置信区间:-28.71 - -20.59;p & lt; 0.01;我²= 83%),non-HDL-C (MD: -31.90%; 95%置信区间:-34.81 - -28.99;p & lt; 0.01; I2 = 0%),和甘油三酸酯水平(MD: -7.21%; 95%置信区间:-11.13 - -3.30;p & lt; 0.01; I2 = 0%)。有趣的是，obicetrapib也降低了新发糖尿病的发病率（RR: 0.88; 95% CI: 0.80 ~ 0.97; p = 0.01; I²= 0%）。相反，obicetrapib显著增加HDL-C （MD: 142.17%; 95% CI: 117.56 ~ 166.78; p < 0.01; I2= 98.3%）、总胆固醇（MD: 11.94%; 95% CI: 5.61 ~ 18.28; p = 0.01; I2= 91%）和载脂蛋白A1浓度（MD: 52.76%; 95% CI: 41.87 ~ 63.66; p < 0.01; I²= 94%）。两组不良事件发生率无显著差异。结论在血脂异常和/或心血管高危患者中，obicetrapib可显著降低LDL-C、脂蛋白(a)、载脂蛋白B和非hdl - c。在不良事件方面没有观察到显著差异，支持obictrapib良好的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊